The landscape of targeted cancer therapy is undergoing a significant paradigm shift following recent clinical disclosures at the European Society…
Read More
Gilead Sciences Secures Global Rights to PepStar’s Oral IL-23 Receptor Inhibitor HCXT-2001 in Landmark $1.275bn Agreement
Gilead Sciences has significantly expanded its footprint in the immunology and inflammatory bowel disease (IBD) therapeutic landscapes through a multi-billion-dollar…
Read More
FDA Approves Cosette Pharmaceuticals Evoxac Oral Solution for Sjögren’s Disease Dry Mouth
Cosette Pharmaceuticals has secured a significant regulatory milestone with the United States Food and Drug Administration (FDA) granting approval for…
Read More
The oral exposure challenge in PROTACs: What drug developers need to solve early
Proteolysis Targeting Chimera (PROTAC) technology has transitioned from a theoretical breakthrough in chemical biology to a validated clinical reality. In…
Read MoreThe oral exposure challenge in PROTACs: What drug developers need to solve early
Proteolysis Targeting Chimera (PROTAC) technology has officially transitioned from a visionary academic concept to a cornerstone of modern clinical pharmacology.…
Read More
Novo Nordisk Expands Cardiometabolic Portfolio With $2.3bn Hengrui Licensing Deal for Once-Weekly Oral GLP-1/GIP Agonist HRS-1596
In a strategic move to cement its leadership in the booming cardiometabolic therapeutics market, Danish pharmaceutical titan Novo Nordisk has…
Read More
Navigating the Evolution of Oral Solid Dose Pharmaceuticals: CDMOs and Sponsors Face New Demands in Packaging, Sustainability, and Scaling
The pharmaceutical landscape is undergoing a structural realignment, anchored by the resurgence of oral solid dosage (OSD) platforms and the…
Read More
The oral exposure challenge in PROTACs: What drug developers need to solve early
The landscape of modern pharmacology shifted fundamentally in May 2026 with the U.S. Food and Drug Administration’s approval of vepdegestrant,…
Read More
The oral exposure challenge in PROTACs: What drug developers need to solve early
The landscape of modern pharmacology shifted fundamentally in May 2026, when the U.S. Food and Drug Administration (FDA) granted approval…
Read More
Sling Therapeutics Secures $123M in Series C Financing to Advance Pivotal Phase III Trial of First-in-Class Oral TED Treatment
Sling Therapeutics has closed a significant $123 million Series C financing round, directing the capital toward the pivotal late-stage clinical…
Read More
